SINOPHARM (01099) announced its performance for the first three quarters, with a net profit attributable to the parent company of approximately 5.307 billion yuan, an increase of 0.53% year-on-year.

SINOPHARM (01099) announced its performance for the first 9 months before 2025. The operating income was approximately 431.479 billion yuan, a decrease of 2.47% year-on-year; the net profit attributable to the owners of the parent company was approximately 5.307 billion yuan, an increase of 0.53% year-on-year; basic earnings per share were 1.7 yuan.